SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile

Objectives: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. Methods: This study exa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vimvara Vacharathit, Sirawat Srichatrapimuk, Suwimon Manopwisedjaroen, Suppachok Kirdlarp, Chanya Srisaowakarn, Chavachol Setthaudom, Nanthicha Inrueangsri, Prapaporn Pisitkun, Mongkol Kunakorn, Suradej Hongeng, Somnuek Sungkanuparph, Arunee Thitithanyanont
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	SARS-CoV-2 COVID-19 disease severity Neutralizing antibodies Neutralization kinetics Cytokines Cytokine storm Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/a00a1138c3ac4228a1bea8270b8ee403
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a00a1138c3ac4228a1bea8270b8ee403
record_format	dspace
spelling	oai:doaj.org-article:a00a1138c3ac4228a1bea8270b8ee4032021-11-30T04:14:13ZSARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile1201-971210.1016/j.ijid.2021.09.021https://doaj.org/article/a00a1138c3ac4228a1bea8270b8ee4032021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007293https://doaj.org/toc/1201-9712Objectives: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. Methods: This study examined the longitudinal profiles of neutralizing antibody (NAb) titers in hospitalized COVID-19 patients clinically diagnosed with mild symptoms, pneumonia, or severe pneumonia, up to 12 months after illness onset, using live-virus neutralization. Multiplex, correlation, and network analyses were used to characterize serum-derived inflammatory cytokine profiles in all severity groups. Results: Peak NAb titers correlated with disease severity, and NAb titers declined over the course of 12 months regardless of severity. Multiplex analyses revealed that IP-10, IL-6, IL-7, and VEGF-α were significantly elevated in severe pneumonia cases compared to those with mild symptoms and pneumonia cases. Correlation and network analyses further suggested that cytokine network formation was distinct in different COVID-19 severity groups. Conclusions: The study findings inform on the long-term kinetics of naturally acquired serological immunity against SARS-CoV-2 and highlight the importance of identifying key cytokine networks for potential therapeutic immunomodulation.Vimvara VacharathitSirawat SrichatrapimukSuwimon ManopwisedjaroenSuppachok KirdlarpChanya SrisaowakarnChavachol SetthaudomNanthicha InrueangsriPrapaporn PisitkunMongkol KunakornSuradej HongengSomnuek SungkanuparphArunee ThitithanyanontElsevierarticleSARS-CoV-2COVID-19 disease severityNeutralizing antibodiesNeutralization kineticsCytokinesCytokine stormInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 112, Iss , Pp 227-234 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 disease severity Neutralizing antibodies Neutralization kinetics Cytokines Cytokine storm Infectious and parasitic diseases RC109-216
spellingShingle	SARS-CoV-2 COVID-19 disease severity Neutralizing antibodies Neutralization kinetics Cytokines Cytokine storm Infectious and parasitic diseases RC109-216 Vimvara Vacharathit Sirawat Srichatrapimuk Suwimon Manopwisedjaroen Suppachok Kirdlarp Chanya Srisaowakarn Chavachol Setthaudom Nanthicha Inrueangsri Prapaporn Pisitkun Mongkol Kunakorn Suradej Hongeng Somnuek Sungkanuparph Arunee Thitithanyanont SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
description	Objectives: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. Methods: This study examined the longitudinal profiles of neutralizing antibody (NAb) titers in hospitalized COVID-19 patients clinically diagnosed with mild symptoms, pneumonia, or severe pneumonia, up to 12 months after illness onset, using live-virus neutralization. Multiplex, correlation, and network analyses were used to characterize serum-derived inflammatory cytokine profiles in all severity groups. Results: Peak NAb titers correlated with disease severity, and NAb titers declined over the course of 12 months regardless of severity. Multiplex analyses revealed that IP-10, IL-6, IL-7, and VEGF-α were significantly elevated in severe pneumonia cases compared to those with mild symptoms and pneumonia cases. Correlation and network analyses further suggested that cytokine network formation was distinct in different COVID-19 severity groups. Conclusions: The study findings inform on the long-term kinetics of naturally acquired serological immunity against SARS-CoV-2 and highlight the importance of identifying key cytokine networks for potential therapeutic immunomodulation.
format	article
author	Vimvara Vacharathit Sirawat Srichatrapimuk Suwimon Manopwisedjaroen Suppachok Kirdlarp Chanya Srisaowakarn Chavachol Setthaudom Nanthicha Inrueangsri Prapaporn Pisitkun Mongkol Kunakorn Suradej Hongeng Somnuek Sungkanuparph Arunee Thitithanyanont
author_facet	Vimvara Vacharathit Sirawat Srichatrapimuk Suwimon Manopwisedjaroen Suppachok Kirdlarp Chanya Srisaowakarn Chavachol Setthaudom Nanthicha Inrueangsri Prapaporn Pisitkun Mongkol Kunakorn Suradej Hongeng Somnuek Sungkanuparph Arunee Thitithanyanont
author_sort	Vimvara Vacharathit
title	SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_short	SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_full	SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_fullStr	SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_full_unstemmed	SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_sort	sars‐cov‐2 neutralizing antibodies decline over one year and patients with severe covid‐19 pneumonia display a unique cytokine profile
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/a00a1138c3ac4228a1bea8270b8ee403
work_keys_str_mv	AT vimvaravacharathit sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT sirawatsrichatrapimuk sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT suwimonmanopwisedjaroen sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT suppachokkirdlarp sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT chanyasrisaowakarn sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT chavacholsetthaudom sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT nanthichainrueangsri sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT prapapornpisitkun sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT mongkolkunakorn sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT suradejhongeng sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT somnueksungkanuparph sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile AT aruneethitithanyanont sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
_version_	1718406823237648384

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile

Ejemplares similares